Document Detail


Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial.
MedLine Citation:
PMID:  21048536     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The aim of this prospective, randomized, double-blinded, placebo-controlled single center study was to evaluate an early steroid-free immunosuppression in liver transplant patients.
METHODS: From March 2000 to October 2004, 110 patients were included. All patients received tacrolimus and steroids during the first 2 weeks after orthotopic liver transplantation (OLT). Thereafter, patients in the steroid group (n=54) received steroids and the remaining 56 a placebo. After 6 months, the immunosuppression for all was steroid free. Thirty patients were hepatitis C positive. Five years after inclusion, patient survival, organ survival, steroid side effects, and recirrhosis in hepatitis C virus (HCV) patients were reevaluated.
RESULTS: After 5 years, the following parameters were comparable in both groups: patient survival (P=0.236), organ survival (P=0.509), and acute rejections (P=0.409). Steroid-free immunosuppression lead to a higher rate of chronic rejections (P=0.023). Six months after OLT, there was a difference in rates of posttransplant diabetes mellitus (PTDM) (P=0.024) and hypercholesterolemia (P=0.002). However, 5 years after OLT, there was no difference in hypertension (P=0.647), PTDM (P=0.453), hypercholesterolemia (P=0.412), and osteoporosis (P=0.624). In HCV patients, we could not find any differences in patient survival (P=0.096), organ survival (P=0.424), time free from recirrhosis (P=0.647). The rate of recirrhosis was influenced by steroid bolus therapy (P=0.01) but not by avoiding continuous steroid therapy.
CONCLUSIONS: Early tapering down of steroids to a tacrolimus monotherapy is possible with comparable acute rejection rates. During steroid therapy, PTDM and hypercholesterolemia are cumulative. These side effects are reversible. The recirrhosis in HCV patients is not influenced by continuous steroid therapy but more frequent in HCV patients receiving a steroid bolus therapy.
Authors:
Nina Weiler; Ina Thrun; Maria Hoppe-Lotichius; Tim Zimmermann; Irene Kraemer; Gerd Otto
Related Documents :
23899656 - Fibrinogen level as a surrogate for the outcome of thrombolytic therapy using tissue pl...
22921276 - Risk factors for relaparotomy after cesarean delivery.
15999046 - The effects of steroids on the occurrence of postoperative atrial fibrillation after co...
23187296 - Effect of antithrombin, protein c and protein s on portal vein thrombosis in liver cirr...
21314856 - Effect of warfarin withdrawal on thrombolytic treatment in patients with ischaemic stroke.
18430196 - Predictors of mortality in hiv-infected patients starting antiretroviral therapy in a r...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Transplantation     Volume:  90     ISSN:  1534-6080     ISO Abbreviation:  Transplantation     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-12-16     Completed Date:  2011-01-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0132144     Medline TA:  Transplantation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1562-6     Citation Subset:  IM    
Affiliation:
Department of Transplantation and Hepatobiliarypancreatic Surgery, Hospital of Johannes Gutenberg University Mainz, Mainz, Germany. nina.weiler@unimedizin-mainz.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenal Cortex Hormones / administration & dosage,  therapeutic use*
Diabetes Mellitus / epidemiology,  etiology
Dose-Response Relationship, Drug
Double-Blind Method
Graft Survival / drug effects
Hepatitis C / surgery
Humans
Hypercholesterolemia / epidemiology,  etiology
Immunosuppressive Agents / therapeutic use
Liver Cirrhosis / surgery*
Liver Transplantation / immunology*,  mortality
Postoperative Complications / classification,  epidemiology
Recurrence
Survival Rate
Tacrolimus / therapeutic use*
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Immunosuppressive Agents; 109581-93-3/Tacrolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The indirect alloimmune response causes microvascular endothelial dysfunction-a possible role for al...
Next Document:  Priority setting in health research in Cuba, 2010.